Ser214

Site Information
PsPtsGEsGDLLsNL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 453215

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	293E (epithelial) ( 2 ) , breast ( 1 ) , HeLa (cervical) ( 3 , 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
3	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
4	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info